Skip to main content Back to Top


Reteplase Injection

Reason for the Shortage

    • Chiesi USA acquired Cornerstone Therapeutics in March 2014.
    • Cornerstone Therapeutics acquired EKR Therapeutics in June 2012. EKR Therapeutics had previously purchased Retavase from PDL BioPharma.
    • Cornerstone Therapeutics was seeking FDA approval of a new supplier of the active pharmaceutical ingredient for Retevase:

Available Products

    • Retavase injection, Chiesi, Full Kit, two 10 unit, single dose vial, NDC 10122-0141-02
    • Retavase injection, Chiesi, Half Kit, one 10 unit, single dose vial, NDC 10122-0143-01


Updated June 11, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 9, 2009 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins